Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSE:8747
TSE:8747Capital Markets

Top Asian Dividend Stocks To Consider In February 2026

As global markets navigate a landscape marked by steady interest rates and fluctuating consumer confidence, Asia's economic environment presents unique opportunities for investors seeking stability through dividend stocks. In this context, identifying strong dividend-paying companies can be a strategic move to mitigate volatility and secure consistent income streams amidst evolving market conditions.
TWSE:6412
TWSE:6412Electrical

3 Asian Growth Companies With Insider Ownership Up To 39%

As global markets navigate a period of economic uncertainty, with mixed performances across major indices and regions, Asia's growth companies continue to draw attention for their resilience and potential. In this context, high insider ownership can be an indicator of confidence in a company's future prospects, making it an intriguing factor to consider when evaluating promising stocks in the region.
SZSE:301251
SZSE:301251Electronic

Undiscovered Gems In Asia 3 Small Caps With Promising Potential

As global markets experience varied performances, with small- and mid-cap stocks facing challenges in the U.S., investors are increasingly looking to Asia for opportunities amidst a backdrop of modest growth and evolving economic conditions. In this environment, identifying promising small-cap stocks can hinge on factors such as strong fundamentals, innovative business models, and resilience to broader market fluctuations.
NasdaqCM:SGMO
NasdaqCM:SGMOBiotechs

Assessing Sangamo Therapeutics (SGMO) Valuation After New Fabry Data Financing Move And Leadership Changes

Clinical and financing moves put Sangamo Therapeutics (SGMO) in focus Sangamo Therapeutics (SGMO) moved into the spotlight after releasing detailed Phase 1/2 STAAR study data for its Fabry gene therapy candidate, alongside a US$25 million follow on equity offering and a change in its finance leadership. See our latest analysis for Sangamo Therapeutics. Against this backdrop of clinical data, financing and leadership change, Sangamo Therapeutics’ share price has been under pressure, with a 30...
OM:SF
OM:SFEntertainment

Stillfront Group (OM:SF) Reports SEK 2.4b FY Loss Testing Profit Turnaround Narrative

Stillfront Group (OM:SF) closed out FY 2025 with Q4 revenue of SEK 1.4b and a basic EPS loss of SEK 4.72, alongside trailing 12 month figures showing revenue of SEK 6.1b and a basic EPS loss of SEK 4.75. Over the past six reported quarters, revenue has moved from SEK 1.8b in Q4 2024 to SEK 1.4b in Q4 2025. Quarterly basic EPS has swung between a profit of SEK 0.11 in Q3 2025 and a loss of SEK 14.38 in Q4 2024, setting up a results season where investors are likely to focus heavily on how...